PO.TB10.11 · 肿瘤生物学
Treg-成纤维细胞轴塑造结直肠癌中的免疫抑制性肿瘤微环境
The Treg-fibroblast axis shapes the immunosuppressive tumor microenvironment in colorectal cancer
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
肿瘤微环境(TME)是癌症进展和治疗应答的关键调控因素。癌症相关成纤维细胞(CAFs)是TME中一个异质性且重要的组成部分。在CAFs中,以富含亮氨酸重复序列15(LRRC15)为标志的亚群在肿瘤中富集,并与免疫抑制和免疫治疗耐药有关。然而,LRRC15+ CAFs在TME内的功能相互作用,特别是与调节性T细胞(Tregs)的相互作用,仍未完全理解。虽然已有报道称LRRC15+ CAFs由TGFbeta信号诱导,但我们在小鼠模型中显示,阻断TGFbeta通路并不能逆转LRRC15表达,表明肿瘤微环境中LRRC15+ CAFs的维持并不仅仅依赖于TGFbeta。使用人类肿瘤样本的多组学和空间分析,我们定义了LRRC15+ CAFs的特定分子谱,其与Treg丰度强烈相关,并在TME内频繁显示与Tregs的邻近性。最后,小鼠模型中的功能研究表明,Treg耗竭导致LRRC15+ CAF区室的显著重塑和减少。总之,这些发现揭示了一个Treg-LRRC15+成纤维细胞轴,它通过Treg维持CAF表型来主动塑造结直肠癌的免疫抑制格局,并提示靶向这种相互作用可能在免疫肿瘤学中破坏间质介导的免疫逃逸。
AbbVie披露声明:所有作者均为AbbVie雇员。本研究的设计、研究实施和财务支持由AbbVie提供。AbbVie参与了数据解读、出版物的审阅和批准。
查看英文原文 English abstract
The tumor microenvironment (TME) is a critical regulator of cancer progression and therapeutic response. Cancer-associated fibroblasts (CAFs) are a heterogeneous and significant component of the TME. Among CAFs, the subset marked by leucine-rich repeat containing 15 (LRRC15) is enriched in tumors and has been implicated in immune suppression and resistance to immunotherapy. However, the functional interactions of LRRC15+ CAFs within the TME, particularly with regulatory T cells (Tregs), remain incompletely understood. While it has been reported that LRRC15+ CAFs are induced by TGFbeta signaling, we show in murine models that blockade of TGFbeta pathways does not reverse LRRC15 expression, indicating that maintenance of LRRC15+ CAFs in the tumor microenvironment is not solely dependent on TGFbeta. Using multi-omics and spatial analysis of human tumor samples, we define the specific molecular profile of LRRC15+ CAFs, which strongly correlates with Treg abundance and shows frequent proximity to Tregs within the TME. Finally, functional studies in mouse models demonstrate that Treg depletion leads to pronounced remodeling and reduction of the LRRC15+ CAF compartment. Together, these findings reveal a Treg-LRRC15+ fibroblast axis that actively shapes the immunosuppressive landscape of colorectal cancer via Treg maintenance of CAF phenotype and suggest that targeting this interaction may disrupt stromal-mediated immune evasion in immuno-oncology.
AbbVie Disclosure Statement: All authors are employees of AbbVie. The design, study conduct, and financial support for this research were provided by AbbVie. AbbVie participated in the interpretation of data, review, and approval of the publication.
利益披露 Disclosure
L. Ma,
AbbVie Employment.
M. Bi,
AbbVie Employment.
B. Huang,
AbbVie Employment.
L. Ho,
AbbVie Employment.
H. Lo,
AbbVie Employment.
M. Liao,
AbbVie Employment.
G. Mehta,
AbbVie Employment.
N. Belmar,
AbbVie Employment.
M. Chen,
AbbVie Employment.
T. Anton,
AbbVie Employment.
A. Ammar,
AbbVie Employment.
H. Li,
AbbVie Employment.
K. Halliwill,
AbbVie Employment.
K. MacDonald,
AbbVie Employment.